אולטרסאונד II: אולטרסאונד אנדוסקופי ופיברוסקאן

Endoscopic ultrasound (EUS) integrates optical endoscopy with ultrasonography to visualize the digestive tract and deeper structures. The endoscope provides direct mucosal visualization, while the ultrasound transducer penetrates beyond the gastrointestinal wall to image organs and tissues. High-frequency sound waves (5-20 MHz) reflect off tissues to create detailed cross-sectional images, enabling diagnosis of pancreatic cancer, gastrointestinal tumors, and gallbladder disorders.

Endoscopic ultrasound uses two distinct routes depending on the target area. The oral route passes through the mouth, esophagus, and stomach to access the small intestine and upper digestive structures. The rectal route enters through the anus and rectum to examine the large intestine. Each route allows the echoendoscope to position the ultrasound transducer optimally for imaging specific gastrointestinal regions.

Endoscopic ultrasound excels at visualizing the five distinct layers of the gastrointestinal wall, which is crucial for staging gastrointestinal cancers, especially esophageal, gastric, and rectal cancers. This layered visualization capability allows clinicians to assess tumor depth and invasion, providing essential information for treatment planning and prognosis determination.

Fine needle aspiration (FNA) combines with endoscopic ultrasound to collect tissue samples from lymph nodes or masses using a thin needle passed through the endoscope. This technique is invaluable for staging cancer, diagnosing unexplained masses, and guiding treatment decisions. FNA enables tailored therapeutic strategies based on tissue diagnosis without requiring separate invasive procedures.

FibroScan measures liver stiffness using mechanical vibrations at low frequency (approximately 50 Hz) to generate shear waves. The velocity of these elastic waves correlates with tissue stiffness; stiffer fibrotic tissue produces faster wave travel. This speed converts into a liver stiffness measurement (LSM) in kilopascals, quantifying fibrosis severity in chronic liver diseases like hepatitis B and C.

The controlled attenuation parameter (CAP) is a feature in some FibroScan models that estimates the liver's degree of steatosis, or fat content. CAP provides quantitative assessment particularly useful for diagnosing and monitoring non-alcoholic fatty liver disease (NAFLD). Combined with liver stiffness measurement, CAP offers comprehensive evaluation of both fibrosis and fatty changes in liver tissue.

FibroScan is noninvasive with minimal complication risk compared to liver biopsy, making it more patient-friendly. It samples a larger volume of liver tissue, potentially providing more representative assessment of liver stiffness than biopsy. However, FibroScan may be less accurate in severe obesity or ascites, situations where biopsy might remain necessary for definitive diagnosis.